Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta DrugsNSE:BETA +1.57%92 Earnings per Share (Diluted) is ₹44.21 as of Jun. 2026. GuruFocus rates NSE:BETA with a GF Score™ of 92/100 and a GF Value™ of ₹2,725.95 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 783 Drug Manufacturers companies, Beta Drugs ranks better than 51.98% on this metric.
Beta Drugs's EPS (Basic) for the
three
months ended in Jun. 2026 was ₹14.78.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹44.21.
Beta Drugs's EPS without NRI for the
three
months ended in Jun. 2026 was ₹14.78.
Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was ₹44.21.
During the past 12 months, Beta Drugs's average EPS without NRIGrowth Rate was 30.70% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 10.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 26.90% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 37.20% per year.
During the past 13 years, Beta Drugs's highest 3-Year average EPS without NRI Growth Rate was 480.80% per year. The lowest was 10.40% per year. And the median was 44.00% per year.
Beta Drugs (NSE:BETA) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Beta Drugs Earnings per Share (Diluted) Related Terms
Beta Drugs Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Beta Drugs's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BETA vs ZTS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's PE Ratio distribution charts can be found below:
* The bar in red indicates where Beta Drugs's PE Ratio falls into.
Beta Drugs Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Beta Drugs's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2026 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹44.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of ₹44.21 mean?
Beta Drugs (NSE:BETA) has a Earnings per Share (Diluted) of ₹44.21 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Beta Drugs and its competitors. According to the industry distribution chart, Beta Drugs ranks #376 out of 783 companies in the Drug Manufacturers industry, placing it in the top 48%.
Is Beta Drugs' Earnings per Share (Diluted) too high?
Beta Drugs' current Earnings per Share (Diluted) is ₹44.21. Based on the distribution chart, Beta Drugs ranks #376 out of 783 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beta Drugs has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Earnings per Share (Diluted) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #376 out of 783 companies for Earnings per Share (Diluted). This puts Beta Drugs in the upper half of its industry. The industry median Earnings per Share (Diluted) is 9.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.80, based on 783 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current Earnings per Share (Diluted) is ₹44.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,725.95, compared to a current price of ₹2,118.50 — trading 22.3% below its estimated fair value. The current Earnings per Share (Diluted) is ₹44.21. Beta Drugs' overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Earnings per Share (Diluted) is ₹44.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be undervalued.
The current stock price of ₹2,118.50 is trading 22.3% below its estimated GF Value™ of ₹2,725.95.
GuruFocus considers Beta Drugs to be Modestly Undervalued.
Key valuation signals for NSE:BETA:
Earnings per Share (Diluted): ₹44.21
GF Value™: ₹2,725.95 vs. price of ₹2,118.50 (22.3% below fair value)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
92GF Score
Get the complete analysis for NSE:BETA
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
